Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
BACKGROUND
[3H]-SR 121463 is the first radiolabeled selective nonpeptide vasopressin V2 receptor antagonist ligand that has been reported to date. In the present work, we studied the binding properties of [3H]-SR 121463 for renal V2 receptors from animal and human origins.


METHODS
Binding studies were performed with [3H]-SR 121463 in Chinese hamster ovary (CHO) cells transfected with the human V2 receptor and in various kidney preparations expressing the native V2 receptors (rat, rabbit, dog, pig, monkey, and human). Autoradiographies were performed in rat and human kidney sections.


RESULTS
[3H]-SR 121463 binding to CHO cells stably transfected with the cloned human renal V2 receptor was specific, highly stable, time dependent, saturable, and reversible. A single population of high-affinity binding sites was identified (Kd = 0.94 +/- 0.34 nmol/L, Bmax = 9876 +/- 317 fmol/mg protein). Of note, [3H]-SR 121463 revealed a higher number (about 40%) of V2 sites than [3H]-AVP in the same preparation. Displacement of [3H]-SR 121463 binding by reference peptide and nonpeptide vasopressin/oxytocin compounds exhibited a typical AVP V2 profile. [3H]-SR 121463 also displayed a high affinity for native V2 receptors in several kidney preparations from rat, pig, dog, rabbit, bovine, monkey, and human. The autoradiographic experiments using rat and human kidney sections showed intense labeling in the medullopapillary region and lower intensity in the cortex, consistent with a main localization of V2 receptors on collecting tubules.


CONCLUSIONS
[3H]-SR 121463 is a useful ligand for the specific labeling of animal and human V2 receptors and could be a suitable probe for the search and in situ localization of V2 sites.
Serradeil-Le Gal
C
C
Exploratory Research Department, Sanofi-Synthelabo Recherche, Toulouse, and INSERM U-469, CCIPE, Montpellier, France. claudine.serradeil@sanofi-synthelabo.com
Raufaste
D
D
Double-Cazanave
E
E
Guillon
G
G
Garcia
C
C
Pascal
M
M
Maffrand
J P
JP
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000378:metabolism / Q000494:pharmacology; D001667:Binding, Competitive; D016466:CHO Cells; D002417:Cattle; D006224:Cricetinae; D004285:Dogs; D000882:Haplorhini; D006706:Homeostasis / Q000502:physiology; D006801:Humans; D007668:Kidney / Q000166:cytology / Q000378:metabolism; D007700:Kinetics; D009025:Morpholines / Q000378:metabolism / Q000494:pharmacology*; D011817:Rabbits; D011869:Radioligand Assay; D051381:Rats; D013141:Spiro Compounds / Q000378:metabolism / Q000494:pharmacology*; D013552:Swine; D014316:Tritium; D014667:Vasopressins / Q000502:physiology; D014882:Water-Electrolyte Balance / Q000502:physiology
D065092:Antidiuretic Hormone Receptor Antagonists; D009025:Morpholines; D013141:Spiro Compounds; D014316:Tritium; D014667:Vasopressins; D001127:Arginine Vasopressin; C103281:satavaptan